Jane Street’s Protalix BioTherapeutics PLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$108K Sell
39,200
-100
-0.3% -$249 ﹤0.01% 10537
2026
Q2
$91.6K Sell
39,300
-18,700
-32% -$39.6K ﹤0.01% 10647
2026
Q1
$126K Buy
+58,000
New +$144K ﹤0.01% 10504
2024
Q1
– Sell
-17,100
Closed -$30.4K – 9885
2023
Q4
$30.4K Hold
17,100
– – ﹤0.01% 8864
2023
Q3
$28.4K Sell
17,100
-17,500
-51% -$31.4K ﹤0.01% 8257
2023
Q2
$69.2K Buy
+34,600
New +$82.4K ﹤0.01% 8136
2021
Q4
– Sell
-119,600
Closed -$159K – 10652
2021
Q3
$159K Sell
119,600
-51,600
-30% -$78.4K ﹤0.01% 9022
2021
Q2
$327K Buy
171,200
+140,100
+450% +$482K ﹤0.01% 8001
2021
Q1
$139K Buy
+31,100
New +$145K ﹤0.01% 8497

Other funds holding PLX

Jane Street's PLX Position: Q3 2026 in Review

Jane Street sold out of Protalix BioTherapeutics (PLX) in Q3 2026, closing a stake of 18,020 shares — an estimated $44.8K sold.

Jane Street first reported a position in PLX in Q2 2013 and held it in 48 quarters. The position peaked at $753K in Q1 2025. 107 funds tracked by Wall St. Rank hold PLX as of Q3 2026.

  • Jane Street reported no remaining Protalix BioTherapeutics position as of Q3 2026 after selling out during the quarter.
  • Jane Street sold 18,020 Protalix BioTherapeutics shares in Q3 2026, an estimated $44.8K.
  • Jane Street first reported a position in Protalix BioTherapeutics in Q2 2013 and held it in 48 quarters.
  • Jane Street's Protalix BioTherapeutics position peaked at $753K in Q1 2025.
  • 107 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2026.

Based on Jane Street's 13F filing for Q3 2026, filed 12 Nov 2026.